Browse studies

Find your next paid study

21 recruiting studies matching your filters

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimu…

Metastatic Uveal Melanoma

Estimated

~$10 – $8,750

Replimune, Inc.NCT06581406

Phase 1

A Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that h…

Metastatic Uveal MelanomaUveal Melanoma, MetastaticUveal Melanoma, Recurrent+2 more

Estimated

~$10 – $8,750

Novelwise Pharmaceutical CorporationNCT07136181

Phase 2

Phase 2 Sequential Treatment With Melphalan/HDS Via Percutaneous Hepatic Perfusion Followed by Tebentafusp in the Treatment of Metastatic Uveal Melanoma

This Phase 2 study evaluates the efficacy and safety of sequential treatment with percutaneous hepatic perfusion (PHP) using melphalan/HDS followed by tebentaf…

Metastatic Uveal Melanoma

Estimated

~$10 – $6,250

H. Lee Moffitt Cancer Center and Research InstituteNCT07276386

Observational

Evaluating Immune Response to Percutaneous Hepatic Perfusion With Melphalan for the Treatment of Ocular Melanoma Metastatic to the Liver

This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) for pa…

Uveal Melanoma

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT07364474

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer …

Uveal MelanomaCutaneous MelanomaBAP1 Gene Mutation+5 more

Estimated

~$10 – $1,125

Mohamed Abdel-RahmanNCT04792463

Phase 1

Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the …

Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more

A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dos…

Triple Negative Breast CancerDiffuse Large B Cell LymphomaFollicular Lymphoma+11 more

Estimated

~$10 – $8,750

OncoNano Medicine, Inc.NCT06022029

Phase 3

A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)

Uveal Melanoma

Estimated

~$10 – $8,750

IDEAYA BiosciencesNCT07015190

Phase 2

A Phase II Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spre…

Metastatic Uveal Melanoma

Estimated

~$10 – $6,250

H. Lee Moffitt Cancer Center and Research InstituteNCT06121180